David Kwame Dosoo

David Kwame DosooIt is a great pleasure for me at this time of the year to report on the how the Gallwas membership of the American Association for Clinical Chemistry has benefited me, my laboratory and fellow laboratorians.

I joined the AACC in 2001 through the Gallwas fund. Joining the AACC has had a very profound impact on my career as a clinical laboratory scientist. In 2003 and 2005, I received the AACC International Travel Grant which enabled me to attend the Annual Meetings in Philadelphia and Orlando, respectively. At these meetings, I had the privilege of attending very educative sessions. The sessions on the laboratory’s role in patients’ safety, improving quality in the clinical laboratory and laboratory management were of immense help to me. Apart from the Annual meetings, I have also learnt a lot from the AACC website, the Clinical Chemistry Journal and also from a wide range of books and CDs that I received through the Gallwas membership.

With the Gallwas membership, I am able to get current information on various topics for my lectures to students on our laboratory program. I also make available the Clinical Chemistry journal to colleagues and students. The journal has been very useful to particularly to postgraduate students requiring information for writing their thesis.

The knowledge acquired through the AACC has reflected positively on the quality of work that we perform in our laboratory. In May 2004, I was appointed the Manager of the laboratory of the Research Centre where I have been working since October 2003. With the AACC resources, I have always looking for ways of improving the performance of our laboratory to match up to international standards. I have discussed with colleagues in my laboratory various laboratory topics from the AACC materials on topics such as quality control and quality assurance, safety in the clinical laboratory. I am pleased to say our laboratory is performing very well. Currently, our laboratory is carrying out the analysis of samples as part of a malaria vaccine trial in children between the ages of 5 and 17 months. This trial is being supported by the Glaxosmith Kline (GSK) Biologicals and the Malaria Vaccine Initiative.

Though my Gallwas membership ended in December 2007, I will still continue to be a member of the AACC. I am very grateful to Mr. and Mrs. (Jerry and Sandy) Gallwas for their great thoughtfulness, Van Slyke Foundation, the Executives of the AACC, Mrs. Jean Rhame for the wonderful work they have been doing to ensure that we derive the maximum benefit from the AACC.

I would also like to use this opportunity to invite you to read what the Research Centre where I work is doing to help in improving healthcare by visiting www.ghana-khrc.org.

Page Access: